Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Autolus Logo
Autolus Growth Score
83
CB Rank
35988
Heat Score
67
Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.
Founded
obfuscation
PublicPost-IPO Equity London, England, United Kingdom501-1000 www.autolus.com
Biopharma
Biotechnology
Medical
Pharmaceutical
Overview

Autolus
Total Funding
obfuscation
Growth Score
83
Heat Score
67

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score83
-11 pts
in past quarter
Heat Score 67
1 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Autolus

CB Rank
35988
Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.
Founded
obfuscation
PublicPost-IPO Equity London, England, United Kingdom501-1000 www.autolus.com
Biopharma
Biotechnology
Medical
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Autolus Therapeutics plc
Also Known As Autolus Therapeutics
Operating Status Active
Stock Symbol  NASDAQ:AUTL
Company Type For Profit
Founders  Martin Pule, Tim Funnell
About the Company
Autolus Therapeutics is working on next-generation programmed T cell treatments for the treatment of cancer. The company's pipeline includes Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Autolus was established in 2014 by Tim Funnell and Martin Pule in London, England.
Phone Number +44 (0)20 3829 6230
Contact Email contact@autolus.com
Predictions & Insights

Growth Insight

See this Growth Insight
Autolus is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Obe-cel
A CAR T cell therapy product candidate targeting B-cell malignancies, designed to reprogram patient T cells to recognize and kill cancer cells.
AUTO4
A CAR T cell therapy targeting TRBC1-positive peripheral T-cell lymphoma by reprogramming patient T cells to attack cancer cells expressing the TRBC1 antigen.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 9
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Autolus Logo
Post-IPO Equity - Autolus
—
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 501-1000 Employee Profiles 14 Board Members and Advisors 1 Contacts 348

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 15, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 14, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

7,057
-77.75%
 in past month

IT Spend

$3.4MThis year, Autolus is projected to spend $3.4M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Cost of Living Calculator Logo
Cost of Living Calculator
96
The Sunday Times Logo
The Sunday Times
87
Kanban Logo
Kanban
86

Actively Used Products

13Autolus uses 13 technology products and services including HTML5, Office 365, and  jQuery, according to G2 Stack.

Active Website Tech Count

17Autolus is actively using 17 technologies for its website, according to BuiltWith. These include Microsoft Exchange Online, ASP.NET, and  IIS.

Total IP

192The intellectual property of Autolus includes 177 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, Autolus has registered 15 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Autolus's headquarters? Autolus is located in London, England, United Kingdom.Who invested in Autolus? Autolus has 10 investors including Blackstone Group and  PPF Group.When was the last funding round for Autolus? Autolus closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Autolus's competitors? Alternatives and possible competitors to Autolus may include Harbour Biomed, EQT Life Sciences, and  ImmunityBio.How much funding has Autolus raised to date? Autolus has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(c22f898 1)
|